Merck to Initiate New Phase 3 Clinical Program with Lower Dose …
WEBSep 20, 2022 · RAHWAY, N.J.-- (BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company will initiate a new Phase 3 clinical program with once-daily islatravir for …
Merck Announces Positive Top-Line Results from Pivotal Phase 3 …
WEBOct 25, 2021 · Islatravir is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation for the treatment of people living with HIV-1 infection in combination with other antiretrovirals.
Merck to Initiate New Phase 3 Clinical Program with Lower Dose …
WEBSep 20, 2022 · RAHWAY, N.J.-- ( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company will initiate a new Phase 3 clinical program with...
What can we help you find? - MSD
WEBRAHWAY, N.J., Sept. 20, 2022 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK) announced today that the company will initiate a new Phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection.
Merck Opens Enrollment in New Phase 3 Clinical Trials with ...
WEBFeb 22, 2023 · For more than 35 years, Merck has been committed to scientific research and discovery (R&D) in HIV. Today, we are developing a series of antiviral options designed to help people manage HIV and...
Islatravir plus lenacapavir could be the first once-weekly oral HIV ...
WEBMar 6, 2024 · Islatravir (also known as EFdAor MK-8591) is a first-in-class nucleoside reverse transcriptase translocation inhibitor from Merck. It has a long half-life in the body, making it a candidate for long-acting HIV treatment and prevention.
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment
WEBSep 15, 2024 · Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.
Merck to resume testing of closely watched HIV drug, but at …
WEBSep 20, 2022 · The Food and Drug Administration has allowed Merck & Co. to move forward with testing of its experimental HIV drug islatravir at a lower dose, nearly a year after safety concerns derailed a dozen of the company’s studies.
Merck-Gilead's weekly HIV combo maintains viral suppression
WEBMar 6, 2024 · Early results show that a weekly combination of Merck & Co.’s islatravir and Gilead’s approved HIV med Sunlenca maintained a high rate of viral suppression in patients with HIV, and just one...
Merck Opens Enrollment in New Phase 3 Clinical Trials with ...
WEBFeb 22, 2023 · For more than 35 years, Merck has been committed to scientific research and discovery (R&D) in HIV. Today, we are developing a series of antiviral options designed to help people manage HIV and protect people from HIV, with the goal of reducing the growing burden of infection worldwide.